Executives
-
Galvin RoyPresident, Global Plasma & BC -
Miller Laurie A.SVP, Human Resources
-
Simon, ChristopherPresident & CEO
-
Strong Stewart WPresident, Global Hospital
-
Lingamneni AnilaEVP, Chief Technology Officer
-
Llorens JosepEVP, Global Manufacturing
-
Basil Michelle LEVP and General Counsel
-
Maunsell Farris MaryanneVP, Chief Accounting Officer
-
Darecca JamesEVP, Chief Financial Officer
?
Basil Michelle L
EVP and General Counsel
Haemonetics Corporation
US, Boston [HQ]
CIK
1699629
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
56,005
Price per Share :
$73.49
Equivalence :
$4,115,807.45
Transaction History
-
A56,005 Shares After TransactionValue : $n/a$0.0Transaction Date : 05/28/24
-
Footnotes
-
-
Footnotes:#1 Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024.#2 This number includes unvested restricted stock units ("RSUs") previously reported.#3 Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.#4 Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023).#5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.28 to $88.28, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) and (6) to this Form 4.
-
F44,247 Shares After TransactionValue : $4,235,765.31$1,125,593.34Transaction Date : 05/28/24
-
Footnotes
-
-
Footnotes:#1 Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024.#2 This number includes unvested restricted stock units ("RSUs") previously reported.#3 Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.#4 Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023).#5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.28 to $88.28, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) and (6) to this Form 4.
-
S35,351 Shares After TransactionValue : $3,105,938.86Sold $781,602.56Transaction Date : 05/29/24
-
Footnotes
-
-
Footnotes:#1 Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024.#2 This number includes unvested restricted stock units ("RSUs") previously reported.#3 Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.#4 Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023).#5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.28 to $88.28, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) and (6) to this Form 4.
-
S31,257 Shares After TransactionValue : $2,768,432.49Sold $362,605.58Transaction Date : 05/29/24
-
Footnotes
-
-
Footnotes:#1 Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024.#2 This number includes unvested restricted stock units ("RSUs") previously reported.#3 Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.#4 Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023).#5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.28 to $88.28, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) and (6) to this Form 4.
-
F31,856 Shares After TransactionValue : $3,073,785.44$40,139.84Transaction Date : 05/15/24
-
Footnotes
-
-
Footnotes:#1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.#2 This number includes unvested RSUs previously reported.#3 Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023).